CRPOF: AI 评分 46/100 — AI 分析 (4月 2026)

Ceapro Inc. is a biotechnology company focused on developing and marketing health and wellness products derived from plant extracts. The company operates in the active ingredient product technology and cosmeceutical industries, targeting healthcare and cosmetic sectors.

Key Facts: AI Score: 46/100 Sector: Healthcare

公司概况

概要：

Ceapro Inc. is a biotechnology company specializing in the development and commercialization of plant-derived active ingredients for the healthcare and cosmeceutical industries. With proprietary extraction technologies, Ceapro focuses on oat beta glucan and avenanthramides, targeting markets in the United States, Germany, China, and Canada.

CRPOF是做什么的？

Ceapro Inc., established in 1997 and headquartered in Edmonton, Canada, is a biotechnology company dedicated to the development and marketing of health and wellness products and technologies based on plant extracts. The company operates through two primary segments: Active Ingredient Product Technology Industry and Cosmeceutical Industry. The Active Ingredient Product Technology Industry segment focuses on developing proprietary extraction technologies and applying these technologies to the production, development, and commercialization of active ingredients. Key products include oat beta glucan and avenanthramides, derived from oats and other renewable plant resources, which are utilized in the healthcare and cosmetic industries. The Cosmeceutical Industry segment is involved in the development and commercialization of anti-aging products derived from natural active ingredients. These products are sold directly to end-users primarily through online website sales and through select natural products stores. Ceapro's geographic reach extends to the United States, Germany, China, Canada, and other international markets. The company aims to leverage its proprietary technologies to create value-added products in the health and wellness space.

CRPOF的投资论点是什么？

Ceapro Inc. presents a speculative investment opportunity within the biotechnology sector, driven by its proprietary extraction technologies and focus on plant-derived active ingredients. The company's potential lies in the growing demand for natural and sustainable ingredients in the healthcare and cosmetic industries. However, with a negative P/E ratio of -3.74 and a negative profit margin of -48.9%, the company's financial performance raises concerns. Key growth catalysts include successful commercialization of its active ingredients and expansion into new markets. Investors should carefully consider the risks associated with the company's financial performance and competitive landscape. The company's beta of 1.38 suggests higher volatility compared to the market.

CRPOF在哪个行业运营？

Ceapro Inc. operates within the biotechnology industry, which is characterized by rapid innovation and intense competition. The market for natural and sustainable ingredients in healthcare and cosmetics is growing, driven by consumer demand for cleaner and more environmentally friendly products. Ceapro competes with other biotechnology companies, including ABDXF, AMHV, EIGRQ, LVCLY, and NOXOF, that are also developing and marketing plant-derived active ingredients. The industry is subject to regulatory scrutiny and requires significant investment in research and development.

Biotechnology

Healthcare

CRPOF有哪些增长机遇？

Expansion into New Markets: Ceapro Inc. has the opportunity to expand its geographic reach beyond its current markets in the United States, Germany, China, and Canada. Targeting new markets in Asia and Europe could drive revenue growth and increase market share. The global market for natural ingredients in cosmetics is projected to reach $36 billion by 2027, providing a significant opportunity for Ceapro to capitalize on its plant-derived active ingredients. This expansion could occur within the next 2-3 years.
Development of New Products: Ceapro Inc. can invest in research and development to create new products based on its proprietary extraction technologies. Developing new active ingredients and formulations could attract new customers and increase revenue. The market for anti-aging products is expected to reach $83.2 billion by 2027, offering a significant opportunity for Ceapro to expand its cosmeceutical product line. This development could begin within the next year.
Strategic Partnerships: Ceapro Inc. can form strategic partnerships with other companies in the healthcare and cosmetic industries to expand its distribution network and access new markets. Partnering with established players could accelerate growth and reduce risk. The global market for healthcare partnerships is estimated at $1.2 trillion, indicating substantial opportunities for collaboration. These partnerships could be established within the next 1-2 years.
Increased Online Sales: Ceapro Inc. can focus on increasing its online sales through its website and other e-commerce platforms. Enhancing its online marketing efforts and improving the customer experience could drive revenue growth. The global e-commerce market is projected to reach $6.5 trillion in 2023, providing a significant opportunity for Ceapro to expand its online sales. This initiative can be implemented immediately.
Licensing of Technology: Ceapro Inc. can license its proprietary extraction technologies to other companies in the healthcare and cosmetic industries. Licensing its technology could generate revenue and expand its market reach without requiring significant investment. The global market for technology licensing is estimated at $400 billion, indicating substantial opportunities for Ceapro to monetize its intellectual property. Licensing agreements could be pursued within the next year.

Market Cap of $0.01B indicates a small-cap company with potential for growth but also higher risk.
P/E Ratio of -3.74 reflects negative earnings, suggesting the company is currently not profitable.
Gross Margin of 37.0% indicates the percentage of revenue exceeding the cost of goods sold.
Beta of 1.38 suggests the stock is more volatile than the market average.
Profit Margin of -48.9% indicates significant losses relative to revenue.

CRPOF提供哪些产品和服务？

Develop and market health and wellness products.
Specialize in plant extract-based products.
Operate in the Active Ingredient Product Technology Industry.
Operate in the Cosmeceutical Industry.
Develop proprietary extraction technologies.
Commercialize active ingredients like oat beta glucan and avenanthramides.
Produce anti-aging products derived from natural active ingredients.

CRPOF如何赚钱？

Develop and sell active ingredients to healthcare and cosmetic companies.
Develop and sell cosmeceutical products directly to consumers through online sales.
Generate revenue through the sale of plant-derived active ingredients and cosmeceutical products.

Healthcare companies that use active ingredients in their products.
Cosmetic companies that use active ingredients in their products.
End-users who purchase cosmeceutical products directly through online sales.

Proprietary extraction technologies provide a competitive advantage.
Focus on plant-derived active ingredients aligns with consumer demand for natural products.
Established presence in the healthcare and cosmetic industries.

什么因素可能推动CRPOF股价上涨？

Upcoming: Potential regulatory approvals for new active ingredients.
Ongoing: Expansion of online sales and marketing efforts.
Ongoing: Development of new cosmeceutical products.
Upcoming: Announcement of strategic partnerships with other companies.

CRPOF的主要风险是什么？

Potential: Intense competition in the biotechnology industry.
Potential: Regulatory scrutiny and compliance requirements.
Ongoing: Fluctuations in raw material prices.
Ongoing: Negative P/E ratio and profit margin.
Potential: Economic downturns affecting consumer spending.

CRPOF的核心优势是什么？

Proprietary extraction technologies
Focus on plant-derived active ingredients
Presence in multiple geographic markets
Two distinct business segments (Active Ingredient and Cosmeceutical)

CRPOF的劣势是什么？

Negative P/E ratio and profit margin
Small market capitalization
Reliance on online sales for cosmeceutical products
Limited financial resources

CRPOF有哪些机遇？

Expansion into new geographic markets
Development of new products and formulations
Strategic partnerships with other companies
Increased online sales and marketing efforts

CRPOF面临哪些威胁？

Intense competition in the biotechnology industry
Regulatory scrutiny and compliance requirements
Fluctuations in raw material prices
Economic downturns affecting consumer spending

CRPOF的竞争对手是谁？

Abraxas Petroleum Corp. — Energy sector focus, different industry. — (ABDXF)
American Health Ventures Inc. — Venture capital firm in healthcare. — (AMHV)
Eiger BioPharmaceuticals Inc. — Focus on late-stage drug development. — (EIGRQ)
LivaNova PLC — Medical technology company. — (LVCLY)
Noxopharm Ltd. — Australian drug development company. — (NOXOF)

Key Metrics

MoonshotScore: 46/100

Company Profile

CEO: Gilles R. Gagnon
Headquarters: Edmonton, CA
Founded: 2021

AI Insight

AI analysis pending for CRPOF

OTC Tier: OTC Other
Disclosure Status: Unknown

常见问题

What does Ceapro Inc. do?

Ceapro Inc. is a biotechnology company that develops, manufactures, and markets active ingredients and cosmeceutical products derived from plant extracts. The company operates through two segments: Active Ingredient Product Technology Industry and Cosmeceutical Industry. The Active Ingredient segment focuses on producing ingredients like oat beta glucan for the healthcare and cosmetic industries, while the Cosmeceutical segment develops and sells anti-aging products directly to consumers, primarily through online channels. Ceapro's core competency lies in its proprietary extraction technologies that enable the production of high-value ingredients from renewable plant resources.

What do analysts say about CRPOF stock?

As of 2026-03-17, there is no readily available analyst consensus on CRPOF stock, likely due to its OTC listing and small market capitalization. Key valuation metrics, such as the negative P/E ratio, indicate that the company is currently not profitable. Growth considerations revolve around the successful commercialization of its active ingredients, expansion into new markets, and the development of new products. Investors should conduct their own thorough research and consider the risks associated with investing in a small-cap, OTC-listed company in the biotechnology sector.

What are the main risks for CRPOF?

The main risks for Ceapro Inc. include intense competition in the biotechnology and cosmeceutical industries, regulatory scrutiny and compliance requirements, fluctuations in raw material prices, and the company's current lack of profitability. As an OTC-listed company, CRPOF also faces risks related to limited liquidity, potential for price volatility, and reduced transparency compared to companies listed on major exchanges. Furthermore, the company's reliance on online sales for its cosmeceutical products makes it vulnerable to changes in consumer behavior and competition from other online retailers.